Early triage of patients diagnosed with COVID-19 based on predicted prognosis: A Korean national cohort study

Abstract

We developed a tool for early triage of a COVID-19 patient based on a predicted prognosis, using a Korean national cohort of 5,596 patients. Predictors chosen for our model were older age, male sex, subjective fever, dyspnea, altered consciousness, temperature ≥ 37.5°C, heart rate ≥ 100 bpm, systolic blood pressure ≥ 160 mmHg, diabetes mellitus, heart disease, chronic kidney disease, cancer, dementia, anemia, leukocytosis, lymphocytopenia, and thrombocytopenia. Our model was better in predicting prognosis than protocols that are not based on data. The AUC of our model utilizing all the selected predictors was 0.907 in predicting whether a patient will require at least oxygen therapy and 0.927 in predicting whether a patient will need critical care or die from COVID-19. Even with age, sex, and symptoms alone used as predictors, AUCs were ≥ 0.88. In contrast, the protocols currently recommended in Korea showed AUCs less than 0.75.
**Introduction**

Since the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) a pandemic in March 2020, it has been raging on, taking the lives of many people (over 1.32 million as of November 17, 2020)\(^1\). However, since no effective anti-viral drug or vaccine has been developed yet, the treatment mainly relies on symptomatic relief and supportive care, oxygen therapy, and critical care, depending on the disease severity. Thus, it is crucial to triage COVID-19 patients rapidly and efficiently so that limited medical resources, including quarantine facilities, hospital beds, and critical care equipment, can be allocated appropriately.

The current protocols recommended for triage and referral of COVID-19 patients in many countries or by WHO are based on known risk factors and expert opinion but have not been validated on the actual patient data\(^2-5\). Furthermore, since sudden disease progression in initially mild or asymptomatic COVID-19 patients is not rare with reported incidences of 6 to 12%\(^6-9\), we should base the triage and referral of COVID-19 patients on the worst severity expected during the disease course, rather than the severity at the time of diagnosis.

The data accumulated for several months now have enabled development of such a data-driven prediction model. Several prediction models for disease severity in COVID-19 patients have been proposed\(^10-15\). There may be limitations, however, to applying these models for COVID-19 patient triage under some real-world circumstances. Most of these models require patients’ information obtained from a blood test or imaging study. However, we often need to triage and refer COVID-19 patients immediately after the diagnosis with limited information depending on the situation.

Therefore, we aimed to develop an easy-to-use tool for COVID-19 patient triage based on a predicted prognosis, with the flexibility to adapt to variable availability. We categorized variables into four groups—demographics and symptoms, underlying diseases, vital signs, and laboratory findings—and develop separate algorithms for different combinations of the
variable groups. We also compared the performance of our models with the currently used triage protocols.

**Materials and Methods**

**Ethical approval**
The Institutional Review Board of *** blinded *** approved this retrospective Health Insurance Portability and Accountability Act-compliant cohort study and waived the informed consent from the participants. We performed all methods in accordance with relevant guidelines and regulations.

**Data source and patients**
This study used a dataset containing the epidemiologic and clinical information of patients diagnosed with COVID-19 in South Korea, which the Korea Disease Control and Prevention Agency (KDCA) collected, anonymized, and provided to researchers for the public interest. The data included 5,628 patients who either were cured or died from COVID-19 infection by April 30, 2020. After excluding 32 patients who lacked the information on disease severity or the presence or absence of symptoms, a total of 5,596 patients comprised our study cohort.

The outcome variable was the worst severity during the disease course, determined by the type of treatment required: (1) none or supportive treatment, (2) oxygen therapy, (3) critical care such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO), or death from COVID-19 infection.

For the development of prediction models, the dataset was randomly divided into training and test cohorts with a ratio of 7:3 while preserving the disease severity distribution. We trained and optimized models using the training cohort and tested them on the test cohort (Fig. 1).
Variables in four different tiers based on accessibility

We intended to develop a model that can be used flexibly in real-world circumstances where some of the variables may not be available. Therefore, we categorized variables into four tiers based on their accessibility (Table 1 and Fig. 1).

Tier 1: Basic demographics and symptoms

Tier 1 variables can be obtained by simply asking a patient questions: age, sex, body mass index (BMI), pregnancy, and symptoms. The symptoms included were subjective fever, cough, sputum, dyspnea, altered consciousness, headache, rhinorrhea, myalgia, sore throat, fatigue, nausea or vomiting, and diarrhea. We separated this group of variables from others because there could be times when we need to triage a patient quickly without physical contact.

Tier 2: Underlying diseases

Tier 2 variables are underlying medical conditions: hypertension, diabetes mellitus (DM), heart disease, asthma, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), chronic liver disease, cancer, autoimmune disease, and dementia. We categorized these variables into a separate group because sometimes patients may not know exactly their underlying medical conditions. In this case, further actions may be required, including reviewing medical records or other examinations.

Tier 3: Vital signs

Tier 3 variables are blood pressure, body temperature, and heart rate. Our data lacked information on breathing rate. We separated these variables from the first two tiers because these can be obtained only when a patient visits a medical facility or can measure their vital
signs on their own. Blood pressure and heart rate were transformed into binary categorical variables by merging categories that were not significantly associated with disease severity based on the preliminary results in the training cohort: severe hypertension (systolic blood pressure ≥160 mmHg) and tachycardia (heart rate ≥100 bpm). We assumed that many patients had their body temperature measured while taking antipyretics, although our data did not contain the information on such patients’ proportion.

**Tier 4: Blood test results**

Tier 4 variables are hemoglobin, hematocrit, white blood cell (WBC) count, lymphocyte count, and platelet count, which are available only after a blood test. As with Tier 3, these variables were also transformed into binary categorical variables: anemia (hematocrit <40%), leukocytosis (WBC ≥11×10³/µL), lymphocytopenia (lymphocyte <1,000/µL), and thrombocytopenia (platelet <150,000/µL).

**Predictor selection**

To identify robust and stable predictors, we repeated 10-fold cross-validation (CV) 100 times with shuffling and choose variables that were selected more than 900 times out of 1,000 trials (>90%) based on two algorithms: Least Absolute Selection and Shrinkage Operator (LASSO) and Random Forest (RF). A variable was selected if its coefficient was non-zero on LASSO, and its variable importance on RF was positive\(^{16,17}\).

**Development of prediction models**

We used four machine learning algorithms: ordinal logistic regression (OLR), multivariate RF, linear support vector machine (L-SVM), and SVM with the radial basis function kernel (R-SVM). For each algorithm, five models were created using one of the following five predictor
sets: predictors chosen from the Tier 1 variables (Model 1), Tiers 1/2 variables (Model 2A), Tiers 1/3 variables (Model 2B), Tiers 1/2/3 variables (Model 3), and Tiers 1/2/3/4 variables (Model 4). We optimized the hyperparameters for RF and SVM through a 10-fold CV with a grid search in the training cohort, using the area under the receiver operator characteristics curve (AUC) as an evaluation metric.

Validation of prediction models in comparison with current protocols

We validated the optimized models in the test cohort after fitting them onto the entire training dataset. Based on the probabilities for each outcome category, we assessed the diagnostic performance of each model for whether or not a patient will require treatment (Outcome 1 vs. 2/3), and whether or not a patient will require critical care or die (Outcome 1/2 vs. 3). Sensitivity, specificity, accuracy, precision, and negative predictive value (NPV) according to different probability cutoffs were calculated, in addition to AUC. We also drew calibration curves to compare the predicted and observed probabilities visually.

As a baseline for comparison, we also tested two protocols used to triage a newly diagnosed COVID-19 patient: a protocol proposed by the Korean Medical Association and Modified Early Warning Score (MEWS)5,18. These are two of the protocols that the Korean government currently recommends using with some modifications depending on the situation5. Since we did not have information on smoking status, oxygen saturation, and respiratory rate, these variables were considered normal when applying the protocols. These protocols are described in detail in Supplementary Tables 1 and 2.

Results

Patients

Of the total 5,596 COVID-19 patients in our study cohort, approximately half of the patients
(52.1%) were 50 years or older, while people aged younger than 20 years accounted for only 4.9% (Table 1). The two most common age groups were 20–29 years (19.8%) and 50-59 years (20.4%). The ratio of males to females was 5.9:4.1. Most (86.4%) recovered without particular therapy, 9.3% of the patients required oxygen therapy, and the remaining 4.4% fell into severe conditions such as respiratory or multi-organ failure and required critical care such as mechanical ventilation or ECMO. The overall mortality from COVID-19 infection was 1.1% (63/5,596). The mean time between diagnosis and recovery or death was 25.6 days, with a standard deviation of 11.0 days. Patients who were older, male, under-weight or obese, or with symptoms (except for diarrhea), underlying diseases (except for autoimmune disease), abnormal vital signs (except for diastolic blood pressure), or abnormal blood test results tended to fall into more severe conditions (Table 1). The training and test cohorts comprised 3,940 and 1,656 patients, respectively. There was no significant difference in variables between the two cohorts (Supplementary Table 3).

Selected predictors for each model

The full results of predictor selection are in Supplementary Table 4.

Model 1: from history taking

The predictors selected from Tier 1 variables for Model 1 were age, sex, and symptoms of subjective fever, rhinorrhea, dyspnea, and altered consciousness. As opposed to other selected predictors, rhinorrhea was associated with a better prognosis (Table 2).

Model 2A: from history taking with known underlying disease status

The predictors chosen for Model2A were age, sex, subjective fever, dyspnea, and altered consciousness from Tier 1 (rhinorrhea excluded), and underlying diseases of hypertension, DM,
heart disease, CKD, cancer, and dementia from Tier 2 variables.

*Model 2B: from history taking and physical examination with uncertain underlying disease*

The predictors were age, sex, subjective fever, rhinorrhea, dyspnea, and altered consciousness from Tier 1, and high body temperature and tachycardia from Tier 3 variables.

*Model 3: from history taking and physical examination with known underlying disease status*

The predictors were age, sex, subjective fever, dyspnea, and altered consciousness from Tier 1 (rhinorrhea not included), severe hypertension (systolic blood pressure ≥160 mmHg), DM, heart disease, CKD, cancer, and dementia from Tier 2, and high body temperature and tachycardia from Tier 3.

*Model 4: on admission*

The predictors were age, sex, subjective fever, dyspnea, and altered consciousness from Tier 1, severe hypertension, DM, heart disease, CKD, cancer, and dementia from Tier 2, and high body temperature from Tier 3 (tachycardia excluded), and anemia, leukocytosis, lymphocytopenia, and thrombocytopenia from Tier 4 variables.

*Variable effect size*

Older age, altered consciousness, dyspnea, lymphocytopenia, leukocytosis, CKD, temperature of ≥38.5°C, dementia, thrombocytopenia, cancer, subjective fever, male sex, anemia, DM were associated independently with prognosis, in decreasing order of odds ratio (OR) from the multivariable OLR in the entire cohort (Table 2). Figure 2 is a flow diagram that shows the prognosis of different patient groups classified according to the age and the presence or absence of the symptoms and underlying diseases.
Model performance

Conventional protocols

In predicting whether a patient will require more than supportive care, the KMA model showed an AUC of 0.723 (95% confidence interval [CI], 0.693–0.753) with a sensitivity of 54.9 (48.3–61.4)%, and a specificity of 7.6 (6.3–9.1)%, and the AUC, sensitivity, and specificity of the MEWS were 0.598 (0.563–0.633), 56.8 (50.1–63.4)%, and 23.5 (21.2–25.9)%, respectively. The performances of these two conventional models were not significantly different in predicting whether or not a patient will need critical care or die (Table 3).

Machine learning models

Machine learning models showed better performances than the conventional protocols (Table 3 and Supplementary Table 4). With the OLS algorithm, the AUCs of Models 1, 2A, 2B3, and 4 were 0.880 (95% CI, 0.855–0.904), 0.889 (0.865–0.912), 0.866 (0.841–0.892), 0.894 (0.871–0.917), and 0.907 (0.884–0.929) in predicting whether a patient will require at least oxygen therapy, and 0.903 (0.869–0.937), 0.905 (0.869–0.940), 0.922 (0.892–0.953), and 0.927 (0.894–0.960) in predicting whether a patient will need critical care or die, respectively (Table 3). The other machine learning algorithms—RF, L-SVC, and R-SVC—did not show superior performances to the OLS model (Supplementary Table 5).

The sensitivity, specificity, accuracy, precision, and NPV at different cutoff probabilities for the OLS models are presented in Table 4. The models showed good calibration in the training and testing, especially in the probability range of < 50% (Fig. 3). Figure 4 shows the nomogram of OLS Model 4 to predict the probability of recovering without particular treatment and the probability of requiring critical care or death from COVID-19 (see Supplementary Figure 1 for the nomograms of all the five models). When using a computer
device, it can be coded to choose an appropriate model automatically depending on available predictors; a simplified Python code with coefficients trained onto the entire dataset can be found in *** blinded ***.

**Discussion**

Our results demonstrate that a data-driven model to predict prognosis can be a good tool for early triage of COVID-19 patients. A significant shortcoming of the triage protocols that are not based on data is that risk factors are not weighted appropriately based on their effects on the outcome. For example, the WHO algorithm for COVID-19 triage and referral regards age > 60 years and the presence of relevant symptoms or co-morbidities as risk factors, but it does not put different weights on them. However, if not treated as a continuous variable, age should be divided into multiple categories with appropriate weights because the risk continues to increase with age even after 60 years. Different symptoms or co-morbidities must also be weighted according to their importance when assessing the patients’ status for triage. For example, in the current study, subjective fever, dyspnea, and altered consciousness were independent risk factors for severe illness, while other symptoms such as cough, sputum production, sore throat, myalgia, and diarrhea were not.

Our final prediction model used the OLR algorithm. We chose the OLR over the other machine learning algorithms (i.e., RF, L-SVM, and R-SVM) because it showed comparable or superior performances to the other algorithms in the final evaluation. Furthermore, a linear model like the OLR is more interpretable and easier to use even without a computer device, as nomograms can be used instead. We also observed the linear model’s superiority in predicting COVID-19 prognosis in our previous study in which we developed a model to predict the risk of COVID-19 mortality based on demographics and medical claim data.

A difference of the current model from other earlier models is that we divided disease
severity into three categories. This is more helpful than the binary categorization (i.e., recovery vs. mortality), because not all medical facilities capable of oxygen therapy can also provide critical care, such as mechanical ventilation or ECMO. Furthermore, our model uses different algorithms depending on the available variable subsets. Health workers sometimes need to triage newly diagnosed COVID-19 patients even by a phone call alone in the real-world field, and patients commonly do not know their underlying disease exactly. Therefore, we expect that our model’s flexibility may lead to a more widespread use.

The predictors chosen in this study are not much different from the known risk factors of developing into critical conditions from COVID-19. However, it was unexpected that COPD, a known strong risk factor, was not selected as a predictor. We assume that this is because there were only 40 patients with COPD in the entire cohort, of whom 65% had dyspnea, and the disease severity of COPD might have varied widely. Thus, it is likely that the number of COPD cases was too small (even smaller in the training cohort after the training-test set split) to play a significant role independently from the other strong predictors. We hope to have more confirmatory results through further investigation as the KDCA plans to release the enhanced data with more patients soon.

There are limitations to our current model. First, we need to develop a more robust model by enrolling more patients and conduct prospective validation. We plan to use the current model in actual practice and keep improving the model using the newly accumulated data. Second, since we trained our model on Koreans’ data, it is unsure whether it can be generalizable to patient cohorts in other countries or races. We hope to be able to develop a triage model that can be used globally through collaboration. Lastly, our data lacked some important variables, such as smoking, respiratory rate, and oxygen saturation, and had missing values in some of the Tiers-2/3/4 variables, which may have affected the training and performance of the algorithms using those variables. We did not perform imputation for
missing values because we did not want the uncertainty and potential bias from imputation, and imputation for missing values did not make significant differences in our preliminary analysis.

In conclusion, we developed a set of models that can be used for disease severity prediction and triage or referral of COVID-19 patients. Our prediction model has a good performance even with age, sex, and symptoms alone. The model performance can be enhanced if further information on underlying disease, vital signs, or blood test results is available.

Acknowledgement

*** blinded *** The authors would like to thank the KCDA for the support and data they kindly provided. The authors alone are responsible for the content of this article.

Author contributions

*** blinded ***

Competing interests

The authors declare no competing interests.
References

1. World Health Organization. Coronavirus (COVID-19) Dashboard. WHO, https://covid19.who.int/ (2020).

2. Algorithm for COVID-19 triage and referral: patient triage and referral for resource-limited settings during community transmission. WHO, https://apps.who.int/iris/handle/10665/331915 (2020).

3. Guidance for U.S. Healthcare Facilities about Coronavirus (COVID-19). CDC, https://www.cdc.gov/coronavirus/2019-ncov/hcp/us-healthcare-facilities.html (2020).

4. Coronavirus (COVID-19) clinical triage support tool. NHS Digital, https://digital.nhs.uk/services/covid-19-clinical-triage-support-tool (2020).

5. Coronavirus Disease-19, Republic of Korea. MOHW, http://ncov.mohw.go.kr/en/ (2020).

6. Chen, L. et al. Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China. *Immun Inflamm Dis* 8, 584–594 (2020).

7. Suh, H. J. et al. Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance. *J Korean Med Sci* 35, e297 (2020).

8. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239–1242 (2020).

9. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 395, 1054–1062 (2020).

10. Feng, Z. et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. *Nat Commun* 11, 4968 (2020).
11. Liang, W. et al. Early triage of critically ill COVID-19 patients using deep learning. *Nat Commun* **11**, 3543 (2020).

12. Barda, N. et al. Developing a COVID-19 mortality risk prediction model when individual-level data are not available. *Nat Commun* **11**, 4439 (2020).

13. Gong, J. et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. *Clin Infect Dis* **28**, 833–840 (2020). doi:10.1093/cid/ciaa443.

14. Yan, L. et al. An interpretable mortality prediction model for COVID-19 patients. *Nat Mach Intell* **2**, 283-288(2020). doi:10.1038/s42256-020-0180-7.

15. *** blinded ***

16. Tibshirani, R. Regression shrinkage and selection via the lasso: a retrospective. *J Royal Statistical Soc Ser B Statistical Methodol* **73**, 273–282 (2011).

17. Bureau, A. et al. Identifying SNPs predictive of phenotype using random forests. *Genet Epidemiol* **28**, 171–182 (2005).

18. Subbe, C. P., Kruger, M., Rutherford, P. & Gemmel, L. Validation of a modified Early Warning Score in medical admissions. *Qjm Int J Medicine* **94**, 521–526 (2001).

19. Liu, D. et al. Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study. *EClinicalMedicine* **25**, 100471 (2020).
# Tables

## Table 1. Patient characteristics by the worst severity during the disease course

| Variable                  | Supportive care | O₂ therapy | Critical care | Mortality | p-value | Total       |
|---------------------------|-----------------|------------|---------------|-----------|---------|-------------|
| Number of patients        | 4780 (85.6%)    | 512 (9.1%) | 241 (4.3%)    | 63 (1.1%) | <0.001  | 5596 (100%) |
| Days to recovery or death, mean (SD) | 25.5 (10.3)    | 30.0 (12.1) | 36.3 (16.1)  | 15.2 (13.4) | <0.001  | 25.6 (11.0) |
| Age                       |                 |            |               |           |         |             |
| 0-9 years                 | 66 (100%)       | 0 (0%)     | 0 (0%)        | 0 (0%)    | <0.001  | 66 (100%)   |
| 10-19 years               | 203 (99%)       | 1 (0.5%)   | 0 (0%)        | 1 (0.5%)  | 205 (100%) |
| 20-29 years               | 1087 (98%)      | 20 (1.8%)  | 0 (0%)        | 2 (0.2%)  | 1109 (100%) |
| 30-39 years               | 546 (97.2%)     | 11 (2%)    | 2 (0.4%)      | 3 (0.5%)  | 562 (100%) |
| 40-49 years               | 703 (95.1%)     | 34 (4.6%)  | 2 (0.3%)      | 0 (0%)    | 739 (100%) |
| 50-59 years               | 999 (87.6%)     | 114 (10%)  | 15 (1.3%)     | 12 (1.1%) | 1140 (100%) |
| 60-69 years               | 713 (78.7%)     | 135 (14.9%)| 34 (3.8%)     | 24 (2.6%) | 906 (100%) |
| 70-79 years               | 331 (60.7%)     | 125 (22.9%)| 73 (13.4%)    | 16 (2.9%) | 545 (100%) |
| ≥80 years                 | 132 (40.7%)     | 72 (22.2%) | 115 (35.5%)   | 5 (1.5%)  | 324 (100%) |
| Sex                       |                 |            |               |           |         |             |
| Female                    | 2858 (86.9%)    | 288 (8.8%) | 114 (3.5%)    | 29 (0.9%) | <0.001  | 3289 (100%) |
| Male                      | 1922 (83.3%)    | 224 (9.7%) | 127 (5.5%)    | 34 (1.5%) | 2307 (100%) |
| Pregnancy                 |                 |            |               |           |         |             |
| No                        | 4752 (85.3%)    | 512 (9.2%) | 241 (4.3%)    | 63 (1.1%) | 0.353   | 5568 (100%) |
| Yes                       | 19 (100%)       | 0 (0%)     | 0 (0%)        | 0 (0%)    | 19 (100%) |
| Missing                   | 9 (100%)        | 0 (0%)     | 0 (0%)        | 0 (0%)    | 9 (100%)  |
| Body mass index (kg/cm²)  |                 |            |               |           |         |             |
| <18.5                     | 225 (86.9%)     | 16 (6.2%)  | 16 (6.2%)     | 2 (0.8%)  | <0.001  | 259 (100%) |
| 18.5-23                   | 1660 (89.5%)    | 127 (6.9%) | 46 (2.5%)     | 21 (1.1%) | 1854 (100%) |
| 23-25                     | 893 (86.4%)     | 108 (10.5%)| 20 (1.9%)     | 12 (1.2%) | 1033 (100%) |
| 25-30                     | 865 (82.8%)     | 125 (12%)  | 39 (3.7%)     | 16 (1.5%) | 1045 (100%) |
| ≥30                       | 178 (86%)       | 20 (9.7%)  | 5 (2.4%)      | 4 (1.9%)  | 207 (100%) |
| Missing                   | 959 (80.1%)     | 116 (9.7%) | 115 (9.6%)    | 8 (0.7%)  | 1198 (100%) |
| Subjective fever          |                 |            |               |           |         |             |
| Absent                    | 3818 (88.9%)    | 296 (6.9%) | 148 (3.4%)    | 32 (0.7%) | <0.001  | 4294 (100%) |
| Present                   | 962 (73.9%)     | 216 (16.6%)| 93 (7.1%)     | 31 (2.4%) | 1302 (100%) |
| Cough                     |                 |            |               |           |         |             |
| Absent                    | 2836 (86.9%)    | 239 (7.3%) | 160 (4.9%)    | 30 (0.9%) | <0.001  | 3265 (100%) |
| Present                   | 1944 (83.4%)    | 273 (11.7%)| 81 (3.5%)     | 33 (1.4%) | 2331 (100%) |
| Sputum                    |                 |            |               |           |         |             |
| Absent                    | 3456 (86.7%)    | 319 (8%)   | 169 (4.2%)    | 41 (1%)   | <0.001  | 3985 (100%) |
| Present                   | 1324 (82.2%)    | 193 (12%)  | 72 (4.5%)     | 22 (1.4%) | 1611 (100%) |
| Dyspnea                   |                 |            |               |           |         |             |
| Absent                    | 4445 (90.1%)    | 332 (6.7%) | 128 (2.6%)    | 26 (0.5%) | <0.001  | 4931 (100%) |
| Present                   | 335 (50.4%)     | 180 (27.1%)| 113 (17%)     | 37 (5.6%) | 665 (100%) |
| Sore throat               |                 |            |               |           |         |             |
| Absent                    | 3989 (84.4%)    | 446 (9.4%) | 228 (4.8%)    | 61 (1.3%) | <0.001  | 4724 (100%) |
| Present                   | 791 (90.7%)     | 66 (7.6%)  | 13 (1.5%)     | 2 (0.2%)  | 872 (100%) |
| Rhinorrhea                |                 |            |               |           |         |             |
| Absent                    | 4216 (84.7%)    | 468 (9.4%) | 235 (4.7%)    | 60 (1.2%) | <0.001  | 4979 (100%) |
| Condition                        | Present | Absent | | Present | Absent | | Present | Absent | | Present | Absent | | Present | Absent | | Present | Absent |
|---------------------------------|---------|--------| |---------|--------| |---------|--------| |---------|--------| |---------|--------| |---------|--------|
| Heart rate                      | 564 (91.4%) | 44 (7.1%) | 6 (1%) | 3 (0.5%) | 617 (100%) |
| Dementia                        | 4005 (85.6%) | 400 (8.6%) | 220 (4.7%) | 52 (1.1%) | <0.001 | 4677 (100%) |
| Autoimmune disease              | 775 (84.3%) | 112 (12.2%) | 21 (2.3%) | 11 (1.2%) | 919 (100%) |
| Cancer                          | 4606 (85.9%) | 475 (8.9%) | 224 (4.2%) | 58 (1.1%) | <0.001 | 5363 (100%) |
| Pulmonary obstructive asthma    | 174 (74.7%) | 37 (15.9%) | 17 (7.3%) | 5 (2.1%) | 233 (100%) |
| Headache                        | 3931 (84.8%) | 421 (9.1%) | 228 (4.9%) | 53 (1.1%) | <0.001 | 4633 (100%) |
| Nausea or vomiting              | 849 (88.2%) | 91 (9.4%) | 13 (1.3%) | 10 (1%) | 963 (100%) |
| Diabetes                        | 4598 (85.9%) | 470 (8.8%) | 225 (4.2%) | 59 (1.1%) | <0.001 | 5352 (100%) |
| Myalgia                         | 4354 (85.7%) | 446 (8.8%) | 223 (4.4%) | 57 (1.1%) | 0.022 | 5080 (100%) |
| Diabetes mellitus               | 4772 (85.8%) | 512 (9.2%) | 218 (3.9%) | 59 (1.1%) | <0.001 | 5561 (100%) |
| Altered consciousness           | 8 (22.9%) | 0 (0%) | 23 (65.7%) | 4 (11.4%) | 35 (100%) |
| Hypertension                    | 4322 (88%) | 397 (8.1%) | 143 (2.9%) | 47 (1%) | <0.001 | 4909 (100%) |
| Heart disease                   | 4358 (66.7%) | 115 (16.7%) | 98 (14.3%) | 16 (2.3%) | 687 (100%) |
| Diabetes mellitus               | 3966 (90.2%) | 304 (6.9%) | 97 (2.2%) | 31 (0.7%) | <0.001 | 4398 (100%) |
| Heart disease                   | 814 (67.9%) | 208 (17.4%) | 144 (12%) | 32 (2.7%) | 1198 (100%) |
| Diabetes mellitus               | 4756 (85.9%) | 497 (9%) | 223 (4%) | 61 (1.1%) | <0.001 | 5537 (100%) |
| Heart disease                   | 24 (40.7%) | 15 (25.4%) | 18 (30.5%) | 2 (3.4%) | 59 (100%) |
| Diabetes mellitus               | 4682 (85.6%) | 495 (9.1%) | 228 (4.2%) | 63 (1.2%) | 0.001 | 5468 (100%) |
| Heart disease                   | 98 (76.6%) | 17 (13.3%) | 13 (10.2%) | 0 (0%) | 128 (100%) |
| Chronic obstructive pulmonary disease | 4760 (85.7%) | 502 (9%) | 233 (4.2%) | 61 (1.1%) | <0.001 | 5556 (100%) |
| Chronic kidney disease          | 4757 (85.9%) | 498 (9%) | 225 (4.1%) | 61 (1.1%) | <0.001 | 5541 (100%) |
| Cancer                          | 23 (41.8%) | 14 (25.5%) | 16 (29.1%) | 2 (3.6%) | 55 (100%) |
| Cancer                          | 4679 (85.8%) | 490 (9%) | 219 (4%) | 63 (1.2%) | <0.001 | 5451 (100%) |
| Chronic liver disease           | 101 (69.7%) | 22 (15.2%) | 22 (15.2%) | 0 (0%) | 145 (100%) |
| Chronic liver disease           | 4440 (84.9%) | 490 (9.4%) | 234 (4.5%) | 62 (1.2%) | 0.033 | 5190 (100%) |
| Chronic liver disease           | 61 (73.5%) | 14 (16.9%) | 7 (8.4%) | 1 (1.2%) | 83 (100%) |
| Chronic liver disease           | 315 (97.5%) | 8 (2.5%) | 0 (0%) | 0 (0%) | 323 (100%) |
| Chronic liver disease           | 4430 (84.7%) | 498 (9.5%) | 238 (4.6%) | 63 (1.2%) | 0.356 | 5229 (100%) |
| Chronic liver disease           | 29 (76.3%) | 6 (15.8%) | 3 (7.9%) | 0 (0%) | 38 (100%) |
| Chronic liver disease           | 321 (97.6%) | 8 (2.4%) | 0 (0%) | 0 (0%) | 329 (100%) |
| Autoimmune disease              | 4355 (86.3%) | 463 (9.2%) | 166 (3.3%) | 62 (1.2%) | <0.001 | 5046 (100%) |
| Dementia                        | 107 (47.8%) | 41 (18.3%) | 75 (33.5%) | 1 (0.4%) | 224 (100%) |
| Dementia                        | 318 (97.5%) | 8 (2.5%) | 0 (0%) | 0 (0%) | 326 (100%) |
| Heart rate                      | 87 (80.6%) | 15 (13.9%) | 6 (5.6%) | 0 (0%) | 0.001 | 108 (100%) |
| (beat/min) | Normal (60-100) | Tachycardia (>100) | Missing | 4403 (100%) |
|-----------|-----------------|-------------------|---------|-------------|
|           | 3799 (86.3%)    | 784 (81.8%)       | 110     | 959 (100%)  |
|           | 394 (8.9%)      | 102 (10.6%)       | 1       | 1 (0.8%)    |
|           | 160 (3.6%)      | 61 (6.4%)         | 14      | 1 (0.8%)    |
|           | 50 (1.1%)       | 12 (1.3%)         | 1        | 126 (100%)  |
| Body temperature (°C) | 3799 (86.3%)    | 784 (81.8%)       | 110     | 959 (100%)  |
| <37.5     | 4300 (88.0%)    | 380 (7.8%)        | 166     | 39 (0.8%)   |
| 37.5-38   | 349 (75.4%)     | 70 (15.1%)        | 36      | 8 (1.7%)    |
| 38-38.5   | 74 (54.4%)      | 31 (22.8%)        | 21      | 10 (7.4%)   |
| 38.5>38.5 | 32 (43.8%)      | 29 (39.7%)        | 6       | 6 (8.2%)    |
| Missing   | 25 (64.1%)      | 2 (5.1%)          | 12      | 0 (0%)      |
| Systolic blood pressure (mmHg) | 4300 (88.0%)    | 380 (7.8%)        | 166     | 39 (0.8%)   |
| <120      | 1140 (87.3%)    | 95 (7.3%)         | 58      | 13 (1%)     |
| 120-129   | 988 (86.8%)     | 110 (9.7%)        | 28      | 12 (1.1%)   |
| 130-139   | 939 (86.7%)     | 101 (9.3%)        | 32      | 11 (1%)     |
| 140-159   | 1190 (84%)      | 141 (10%)         | 68      | 18 (1.3%)   |
| ≥160      | 402 (78.4%)     | 65 (12.7%)        | 37      | 9 (1.8%)    |
| Missing   | 121 (87.1%)     | 0 (0%)            | 18      | 0 (0%)      |
| Diastolic blood pressure (mmHg) | 1140 (87.3%)    | 95 (7.3%)         | 58      | 13 (1%)     |
| <80       | 1763 (83.9%)    | 208 (9.9%)        | 104     | 27 (1.3%)   |
| 80-89     | 1557 (86.7%)    | 156 (8.7%)        | 61      | 22 (1.2%)   |
| 90-99     | 907 (86%)       | 102 (9.7%)        | 36      | 10 (0.9%)   |
| ≥100      | 432 (85.7%)     | 46 (9.1%)         | 22      | 4 (0.8%)    |
| Missing   | 121 (87.1%)     | 0 (0%)            | 18      | 0 (0%)      |
| Hemoglobin (g/dL) | 1763 (83.9%)    | 208 (9.9%)        | 104     | 27 (1.3%)   |
| Anemia    | 715 (69.8%)     | 162 (15.8%)       | 128     | 20 (2%)     |
| Normal    | 2137 (84.7%)    | 267 (10.6%)       | 87      | 32 (1.3%)   |
| Elevated  | 471 (88.5%)     | 40 (7.5%)         | 14      | 7 (1.3%)    |
| Missing   | 1457 (96.1%)    | 43 (2.8%)         | 12      | 4 (0.3%)    |
| Hematocrit (%) | 2137 (84.7%)    | 267 (10.6%)       | 87      | 32 (1.3%)   |
| Anemia    | 576 (66.1%)     | 151 (17.3%)       | 124     | 21 (2.4%)   |
| Normal    | 2137 (84.7%)    | 267 (10.6%)       | 87      | 32 (1.3%)   |
| Elevated  | 505 (88.1%)     | 45 (7.9%)         | 16      | 7 (1.2%)    |
| Missing   | 1457 (96.1%)    | 43 (2.8%)         | 12      | 4 (0.3%)    |
| White blood cell count (×10³/µL) | 2137 (84.7%)    | 267 (10.6%)       | 87      | 32 (1.3%)   |
| Leukocytopenia (<4) | 555 (80.6%)    | 99 (14.4%)        | 27      | 8 (1.2%)    |
| Normal (4-11) | 2628 (83.3%)  | 336 (10.7%)       | 149     | 41 (1.3%)   |
| Leukocytosis (≥11) | 141 (59.2%)  | 35 (14.7%)        | 53      | 9 (3.8%)    |
| Missing   | 1456 (96.1%)    | 42 (2.8%)         | 12      | 5 (0.3%)    |
| Lymphocyte count (×10³/µL) | 2628 (83.3%)  | 336 (10.7%)       | 149     | 41 (1.3%)   |
| Lymphocytopenia (<1) | 407 (51.8%)    | 196 (25%)         | 147     | 35 (4.5%)   |
| Normal (1-4.8) | 2871 (88.7%)  | 267 (8.2%)        | 77      | 23 (0.7%)   |
| Lymphocytosis (>4.8) | 33 (100%)     | 0 (0%)            | 0       | 0 (0%)      |
| Missing   | 1469 (95.4%)    | 49 (3.2%)         | 17      | 5 (0.3%)    |
| Platelet count (×10³/µL) | 2871 (88.7%)  | 267 (8.2%)        | 77      | 23 (0.7%)   |
| Thrombocytopenia (<150) | 294 (58.8%)    | 106 (21.2%)       | 85      | 15 (3%)     |
| Normal (150-450) | 2971 (84.7%)  | 352 (10%)         | 142     | 44 (1.3%)   |
| Thrombocytopenia (<150) | 294 (58.8%)    | 106 (21.2%)       | 85      | 15 (3%)     |
| Normal (150-450) | 2971 (84.7%)  | 352 (10%)         | 142     | 44 (1.3%)   |
|                | 59 (81.9%) | 11 (15.3%) | 2 (2.8%) | 0 (0%) | 72 (100%) |
|----------------|------------|------------|----------|--------|-----------|
| Thrombocytosis |            |            |          |        |           |
| (>450)         |            |            |          |        |           |
| Missing        | 1456 (96.1%) | 43 (2.8%) | 12 (0.8%) | 4 (0.3%) | 1515 (100%) |

Values in cells and parentheses are the number and percentage of patients, respectively, except for the days to recovery or death.

* Male, 13.8–17.2 g/dL; Female, 12.1–15.1 g/dL.
** Male, 41–50%; Female, 36–48%
Table 2. Odds ratio of predictors for COVID-19 severity by multivariable ordinal logistic regression in the entire dataset

| Variable                  | Univariable | Multivariable with significant variables in univariable analysis | Multivariable with final predictors |
|---------------------------|-------------|---------------------------------------------------------------|-------------------------------------|
|                           | OR          | p-value            | OR          | p-value | OR          | p-value |
| Age (years)               |             |                    |             |         |             |         |
| <50                       | reference   |                    | reference   |         | reference   |         |
| 50-59                     | 4.787 (3.589-6.385) | <0.001 | 2.802 (1.985-3.954) | <0.001 | 2.820 (2.007-3.962) | <0.001 |
| 60-69                     | 9.264 (7.019-12.227) | <0.001 | 3.954 (2.815-5.555) | <0.001 | 4.057 (2.903-5.67) | <0.001 |
| 70-79                     | 22.777 (17.15-30.251) | <0.001 | 6.867 (4.775-9.875) | <0.001 | 7.173 (5.024-10.243) | <0.001 |
| ≥80                       | 60.557 (44.304-82.773) | <0.001 | 15.463 (10.099-23.675) | <0.001 | 16.528 (10.896-25.071) | <0.001 |
| Sex                       | Female      |                    | Male        |         | Male        |         |
|                           | reference   |                    | 1.345 (1.159-1.561) | <0.001 | 1.520 (1.234-1.873) | <0.001 |
|                           |             |                    | 1.524 (1.244-1.866) | <0.001 |             |         |
| BMI (kg/cm²)              | <23         | reference          |             |         |             |         |
|                           | 1.326 (0.910-1.933) | 0.142 |             |         |             |         |
|                           | 1.324 (0.892-1.963) | 0.163 |             |         |             |         |
|                           | 1.042 (0.612-1.773) | 0.880 |             |         |             |         |
| Subjective fever          | 2.795 (2.394-3.264) | <0.001 | 1.781 (1.321-2.402) | <0.001 | 1.796 (1.338-2.41) | <0.001 |
| Dyspnea                   | 9.017 (7.579-10.727) | <0.001 | 5.241 (4.167-6.591) | <0.001 | 5.712 (4.578-7.127) | <0.001 |
| Altered consciousness     | 51.916 (23.166-116.346) | <0.001 | 11.91 (4.282-33.13) | <0.001 | 13.519 (5.007-36.501) | <0.001 |
| Cough                     | 1.281 (1.104-1.486) | 0.001 | 1.062 (0.843-1.338) | 0.611 |             |         |
| Sputum                    | 1.394 (1.193-1.630) | <0.001 | 1.229 (0.964-1.567) | 0.096 |             |         |
| Sore throat               | 0.544 (0.428-0.693) | <0.001 | 0.792 (0.577-1.086) | 0.147 |             |         |
| Rhinorrhea                | 0.509 (0.381-0.682) | <0.001 | 0.707 (0.475-1.052) | 0.087 |             |         |
| Fatigue                   | 2.042 (1.510-2.762) | <0.001 | 0.985 (0.634-1.53) | 0.945 |             |         |
| Headache                  | 0.733 (0.593-0.904) | 0.004 | 0.763 (0.575-1.013) | 0.062 |             |         |
| Nausea or vomiting        | 2.021 (1.505-2.714) | <0.001 | 1.122 (0.761-1.656) | 0.561 |             |         |
| Myalgia                   | 1.07 (0.880-1.300) | 0.498 |             |         |             |         |
| Diarrhea                  | 1.235 (0.972-1.569) | 0.084 |             |         |             |         |
| Diabetes mellitus         | 3.834 (3.206-4.585) | <0.001 | 1.364 (1.071-1.738) | 0.012 | 1.480 (1.163-1.885) | 0.001 |
| Hypertension              | 4.459 (3.815-5.210) | <0.001 | 1.193 (0.956-1.488) | 0.119 | 1.280 (1.027-1.596) | 0.028 |
| Heart disease             | 9.145 (5.651-14.797) | <0.001 | 1.714 (0.902-3.260) | 0.100 | 1.753 (0.931-3.301) | 0.082 |
| Chronic kidney disease    | 8.653 (5.258-14.239) | <0.001 | 2.351 (1.222-4.523) | 0.010 | 2.443 (1.268-4.706) | 0.008 |
| Cancer                    | 2.736 (1.912-3.914) | <0.001 | 1.654 (1.045-2.618) | 0.032 | 1.835 (1.165-2.892) | 0.009 |
| Dementia                  | 8.091 (6.198-10.562) | <0.001 | 2.214 (1.541-3.183) | <0.001 | 2.257 (1.577-3.230) | <0.001 |
| Asthma                    | 1.844 (1.220-2.787) | 0.004 | 0.911 (0.520-1.596) | 0.744 |             |         |
| COPD                      | 5.978 (3.315-10.78) | <0.001 | 1.431 (0.702-2.916) | 0.324 |             |         |
| Chronic liver disease     | 1.989 (1.222-3.237) | 0.006 | 0.835 (0.437-1.594) | 0.584 |             |         |
|                          | OR (95% CI) | P-value |
|--------------------------|-------------|---------|
| **Autoimmune disease**   | 1.687 (0.802-3.548) | 0.168   |
| **Body temperature (°C)**|             |         |
| <37.5                    | reference   |         |
| 37.5-38.0                | 2.405 (1.918-3.017) | <0.001 |
| 38.0-38.5                | 6.361 (4.544-8.905)  | <0.001 |
| ≥38.5                    | 7.572 (4.974-11.526) | <0.001 |
| **Systolic blood pressure (mmHg)** |         |         |
| <120                     | reference   |         |
| 120-129                  | 0.898 (0.794-1.014)  | 0.083   |
| 130-139                  | 0.935 (0.826-1.058)  | 0.289   |
| 140-159                  | 1.084 (0.966-1.217)  | 0.172   |
| ≥160                     | 1.731 (1.384-2.165)  | <0.001 |
| **Diastolic blood pressure (mmHg)** |         |         |
| ≥100                     | reference   |         |
| 90-99                    | 0.945 (0.802-1.113)  | 0.496   |
| 80-89                    | 0.934 (0.802-1.087)  | 0.377   |
| <80                      | 1.063 (0.915-1.235)  | 0.426   |
| **Heart rate (beat/min)**|             |         |
| 60-100                   | reference   |         |
| <60                      | 1.288 (0.959-1.730)  | 0.093   |
| ≥100                     | 1.406 (1.170-1.689)  | <0.001 |
| **Anemia (based on hematocrit)** |         |         |
|                          | 3.178 (2.682-3.766) | <0.001 |
| **Thrombocytopenia**     | 3.973 (3.266-4.833)  | <0.001 |
| **Leukocytosis**         | 3.800 (2.903-4.973)  | <0.001 |
| **Lymphocytopenia**      | 7.664 (6.437-9.125)  | <0.001 |

OR, odds ratio; BMI, body mass index; COPD, chronic obstructive pulmonary disease.
Table 3. Model performance in early prediction of prognosis in COVID19 patients

| Model    | No significant treatment Vs. O₂ therapy or more | No critical care required Vs. Critical care* or death |
|----------|-----------------------------------------------|-----------------------------------------------------|
|          | AUC   | TP/TN/FP/FN | Sensitivity | Specificity | Accuracy | Precision | NPV       | AUC   | TP/TN/FP/FN | Sensitivity | Specificity | Accuracy | Precision | NPV       |
| OLR      | 0.880 | (0.855-0.904) | 193/1199/236/48 | 80.1% (74.5-84.9) | 83.6% (81.5-85.4) | 83.1% (81.2-84.8) | 45% (40.2-49.8) | 96.2% (94.9-97.1) | 0.900 | (0.869-0.937) | 75/1336/211/3 | 84.3% (75-91.1) | 84.2% (82.3-85.9) | 84.2% (82.4-85.9) | 23% (18.5-28) | 99% (98.3-99.4) |
| Model1   | 0.889 | (0.865-0.912) | 195/1119/209/43 | 81.9% (76.4-86.6) | 84.3% (82.2-86.2) | 83.9% (82.8-85.7) | 48.3% (43.3-53.3) | 96.3% (95.97-97.3) | 0.905 | (0.869-0.94) | 81/1164/13/30 | 91% (83.1-96) | 78.8% (76.6-81.9) | 79.5% (77.4-81.5) | 20% (16.7-24.9) | 99.3% (98.7-99.7) |
| Model2A  | 0.866 | (0.841-0.892) | 181/1147/261/53 | 77.4% (71.4-82.5) | 81.5% (79.3-83.5) | 80.9% (78.9-82.8) | 41% (36.3-45.7) | 95.6% (94.3-96.7) | 0.914 | (0.884-0.944) | 72/1312/47/11 | 84.2% (77.5-92.2) | 84.3% (82.2-85.9) | 83.6% (82.4-86) | 22.6% (18.1-27.6) | 99.2% (98.5-99.6) |
| Model2B  | 0.894 | (0.871-0.917) | 192/1082/210/40 | 82.8% (77.3-87.4) | 83.7% (81.6-85.7) | 84.1% (81.6-85.4) | 47.8% (42.8-52.8) | 96.5% (95.2-97.4) | 0.922 | (0.892-0.953) | 76/1199/242/7 | 91.6% (83.4-96.5) | 83.7% (81.2-85.1) | 83% (81.7-85.5) | 23.9% (19.3-29) | 99.4% (98.8-99.8) |
| Model3   | 0.907 | (0.884-0.929) | 189/835/72/31 | 85.9% (80.6-90.2) | 82.9% (80.5-85.2) | 83.5% (81.3-85.5) | 52.4% (47.1-57.6) | 96.4% (95.97-96.7) | 0.927 | (0.894-0.96) | 68/1046/100/13 | 84% (74.1-91.2) | 91.3% (89.5-92.8) | 90.8% (89-92.3) | 40.5% (33-48.3) | 98.8% (97.9-99.3) |
| KMA model| 0.723 | (0.693-0.753) | 129/108/308/106 | 54.9% (61.4) | 7.6% (6.3-9.148) | 14.4% (12.7-16.1) | 9% (7.5-10.6) | 50.5% (43.6-57.4) | 0.728 | (0.678-0.778) | 43/1395/71/42 | 50.6% (39.5-61.6) | 89.1% (87.4-90.6) | 87.1% (85.4-88.7) | 20.1% (14.9-26.1) | 97.1% (96.1-97.9) |
| MEWS     | 0.598 | (0.563-0.633) | 129/314/202/98 | 56.8% (50.1-63.4) | 23.5% (21.2-25.9) | 28.3% (26.1-30.6) | 11.2% (9.4-13.2) | 76.2% (71.8-80.2) | 0.631 | (0.574-0.689) | 41/1112/71/40 | 50.6% (39.3-61.9) | 75% (72.7-77.2) | 73.7% (71.5-75.9) | 10% (7.2-13.3) | 96.5% (95.3-97.5) |

The results of other machine learning algorithms can be found in Supplementary Table 5. Values in parentheses are 95% confidence intervals. OLR, ordinal logistic regression; AUC, area under the receiver operating characteristics curve; TP, true positive; TN, true negative; FP, false positive; FN, false negative; NPV, negative predictive value; KMA, Korean Medical Association; MEWS, Modified Early Warning Score.

* the use of a ventilator or extracorporeal membrane oxygenation machine.
Table 4. Model performances by cutoff probabilities

| Model   | Cutoff | TP/TN/FP/FN | Sensitivity | Specificity | Accuracy | Precision | NPV | TP/TN/FP/FN | Sensitivity | Specificity | Accuracy | Precision | NPV |
|---------|--------|-------------|-------------|-------------|----------|-----------|-----|-------------|-------------|-------------|----------|-----------|-----|
| **Model 1** | | | | | | | | | | | | | | |
| 5% | 227/714/721/14 | 94.2% (90.4-96.8) | 49.8% (47.1-52.4) | 56.1% (53.7-58.5) | 23.9% (21.3-26.8) | 98.1% (96.8-98.9) | 76/1295/292/13 | 85.4% (76.3-92) | 81.6% (79.6-83.5) | 81.8% (79.9-83.6) | 20.7% (16.6-25.2) | 99% (98.3-99.5) | |
| 10% | 208/1090/345/33 | 86.3% (81.3-90.4) | 76% (73.7-78.1) | 77.4% (75.4-79.4) | 37.6% (33.6-41.8) | 97.1% (95.9-98) | 69/1408/179/20 | 77.5% (67.4-85.7) | 88.7% (87.1-90.2) | 88.1% (86.5-89.6) | 27.8% (22.3-33.8) | 98.6% (97.8-99.1) | |
| 15% | 207/1107/328/34 | 85.9% (80.8-90) | 77.1% (74.9-79.3) | 78.4% (76.4-80.3) | 38.7% (34.5-43) | 97% (95.9-97.9) | 51/1492/95/38 | 57.3% (46.4-67.7) | 94% (92.7-95.1) | 92.1% (90.7-93.3) | 34.9% (27.2-43.3) | 97.5% (96.6-98.2) | |
| 20% | 178/1237/198/63 | 73.9% (67.8-79.3) | 86.2% (84.3-87.9) | 84.4% (82.6-86.1) | 47.3% (42.2-52.5) | 95.2% (93.8-96.3) | 44/1511/76/45 | 49.4% (38.7-60.2) | 95.2% (94-96.2) | 92.8% (91.4-94) | 36.7% (28.1-45.9) | 97.1% (96.1-97.9) | |
| 25% | 168/1277/158/73 | 69.7% (63.5-75.4) | 89% (87.3-90.6) | 86.2% (84.5-87.8) | 51.5% (46-57.1) | 94.6% (93.2-95.7) | 32/1544/43/57 | 36% (26.1-46.8) | 97.3% (96.4-98) | 94% (92.8-95.1) | 47.3% (31.3-54.6) | 96.4% (95.4-97.3) | |
| **Model 2A** | | | | | | | | | | | | | | |
| 5% | 224/711/618/14 | 94.1% (90.3-96.7) | 53.5% (50.8-56.2) | 59.7% (57.2-62.1) | 26.6% (23.6-29.7) | 98.1% (96.8-98.9) | 79/1184/294/10 | 88.8% (80.3-94.5) | 80.1% (78-82.1) | 80.6% (78.6-82.5) | 21.2% (17.1-25.7) | 99.2% (98.5-99.6) | |
| 10% | 212/944/385/26 | 89.1% (84.4-92.7) | 71% (68.5-73.5) | 73.8% (71.5-75.9) | 35.5% (31.7-39.5) | 97.3% (96.1-98.2) | 69/1328/150/20 | 77.5% (67.4-85.7) | 89.9% (88.2-91.3) | 89.2% (87.5-90.6) | 31.5% (25.4-38.1) | 98.5% (97.9-99.1) | |
| 15% | 202/1067/262/36 | 84.9% (79.7-89.2) | 80.3% (78-82.4) | 81% (79-82.9) | 43.5% (39-48.2) | 96.7% (95.5-97.7) | 58/1379/99/31 | 65.2% (54.3-75) | 93.3% (91.9-94.5) | 91.7% (90.2-93) | 36.9% (29.4-45) | 97.8% (96.9-98.5) | |
| 20% | 192/1130/199/46 | 80.7% (75.1-85.5) | 85% (83-86.9) | 84.4% (82.5-86.1) | 49.1% (44-54.2) | 96.1% (94.8-97.1) | 45/1416/62/44 | 50.6% (39.8-61.3) | 95.8% (94.7-96.8) | 93% (91.9-94.4) | 42.1% (32.6-52) | 97% (96.1-97.4) | |
| 25% | 168/1198/131/70 | 70.6% (64.4-76.3) | 90.1% (88.4-91.7) | 87.2% (85.4-88.8) | 56.2% (50.4-61.9) | 94.5% (93.1-95.7) | 40/1431/47/49 | 44.9% (34.4-55.9) | 96.8% (95.8-97.7) | 93.9% (92.6-95) | 46% (35.2-57) | 96.7% (95.6-97.5) | |
| **Model 2B** | | | | | | | | | | | | | | |
| 5% | 254/4317/858/33 | 88.5% (84.2-92) | 83.4% (82.4-84.4) | 83.7% (82.7-84.7) | 22.8% (20.4-25.4) | 99.2% (96.9-99.5) | 736/2680/1986/60 | 92.5% (90.4-94.2) | 57.4% (56-58.9) | 62.5% (61.2-63.8) | 27% (25.4-28.7) | 97.8% (97.2-98.3) | |
| 10% | 225/4676/499/62 | 78.4% (73.2-83) | 90.4% (89.5-91.1) | 89.7% (88.9-90.5) | 31.1% (27.3-34.6) | 98.7% (98.3-99) | 670/3489/1177/126 | 84.2% (81.4-86.6) | 74.8% (73.5-76) | 76.1% (75-77.3) | 36.3% (34.1-38.5) | 96.5% (95.9-97.1) | |
| 15% | 181/4861/314/106 | 63.1% (57.2-68.7) | 93.9% (93.2-94.6) | 92.3% (91.6-93) | 36.6% (32.3-41) | 97.9% (97.4-98.2) | 620/3817/849/176 | 77.9% (74.8-80.7) | 81.8% (80.7-82.9) | 81.2% (80.2-82.3) | 42.2% (39.7-44.8) | 95.6% (94.9-96.2) |
| Model | 5% | 20% |
|-------|----|-----|
|       | 15% | 10% |

| Model 3 | 5% | 20% |
|---------|----|-----|
|         | 15% | 10% |

| Model 4 | 5% | 20% |
|---------|----|-----|
|         | 15% | 10% |

*multi-organ failure, the use of a ventilator or extracorporeal membrane oxygenation machine

TP, true positive; TN, true negative, FP, false positive, FN, false negative; NPV, negative predictive value
Figure legends

Figure 1. Study flow.

5,628 patients who were cured or died from COVID-19 by April 30, 2020 in South Korea

5,596 COVID19 patients

Training cohort (N = 3,940)

Identify variables to predict COVID19 prognosis through repeated 10-fold CV

Test cohort (N = 1,656)

Final testing

Model 1: Tiers 1

Model 2A: Tiers 1, 2

Model 3: Tiers 1, 2, 3

Model 4: All tiers

32 patients excluded due to the lack of information on symptoms or outcome

Tier 1: Obtainable from conversation
- Age and gender
- Symptoms: altered consciousness, dyspnea, fever

Tier 2: May need medical record review or other examinations
- Underlying medical conditions: hypertension, diabetes mellitus, heart disease, chronic kidney disease, cancer, dementia

Tier 3: Physical examination results
- Heart rate >100/min (tachycardia), fever (>37.5°C) regardless of taking antipyretics

Tier 4: Blood test results
- Anemia (Hct <41%), leukocytosis (>11x10^9/µL), lymphocytopenia (<1x10^9/µL), thrombocytopenia (<150/µL)
**Figure 2. Sankey diagram.** Sankey diagram is a type of flow diagram in which the arrows’ width is proportional to the flow rate. This diagram shows that a patient who is older than 50 years and has relevant symptoms or underlying diseases is more likely to require oxygen therapy or critical care.

*Symptoms:* altered consciousness, subjective fever, dyspnea

*Underlying diseases:* diabetes mellitus, hypertension, heart disease, cancer, chronic renal disease, dementia
Figure 3. Calibration plot.
Figure 4. Nomogram of ordinal logistic regression model using all the predictors (Model 4). The nomogram is used by first giving each variable a score on the ‘Point’ scale. The points for all variables are then added to obtain the total points and a vertical line is drawn from the ‘Total points’ row to estimate the probability of requiring treatment and that of requiring critical care or death. The nomograms of the other models can be found in Supplementary Figure 1.